Atectura Breezhaler

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Laadi alla Infovoldik (PIL)
16-10-2023
Laadi alla Toote omadused (SPC)
16-10-2023
Laadi alla Avaliku hindamisaruande (PAR)
23-06-2020

Toimeaine:

indacaterol acetate, Mometasone furoate

Saadav alates:

Novartis Europharm Limited 

ATC kood:

R03AK

INN (Rahvusvaheline Nimetus):

indacaterol, mometasone

Terapeutiline rühm:

Drugs for obstructive airway diseases,

Terapeutiline ala:

Asthma

Näidustused:

Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Toote kokkuvõte:

Revision: 9

Volitamisolek:

Authorised

Loa andmise kuupäev:

2020-05-30

Infovoldik

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 80 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 62.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 160 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 127.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 320 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 260 mcg of mometasone furoate.
Excipient(s) with known effect
Each capsule contains approximately 25 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder, hard capsule (inhalation powder).
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powder, with the
product code “IM150-80”
printed in blue above one blue bar on the body and with the product
logo printed in blue and
surrounded by two blue bars on the cap.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powd
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 80 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 62.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 160 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 127.5 mcg of mometasone furoate.
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder,
hard capsules
Each capsule contains 150 mcg of indacaterol (as acetate) and 320 mcg
of mometasone furoate.
Each delivered dose (the dose that leaves the mouthpiece of the
inhaler) contains 125 mcg of
indacaterol (as acetate) and 260 mcg of mometasone furoate.
Excipient(s) with known effect
Each capsule contains approximately 25 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Inhalation powder, hard capsule (inhalation powder).
Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powder, with the
product code “IM150-80”
printed in blue above one blue bar on the body and with the product
logo printed in blue and
surrounded by two blue bars on the cap.
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder,
hard capsules
Transparent (uncoloured) capsules containing a white powd
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 16-10-2023
Toote omadused Toote omadused bulgaaria 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 23-06-2020
Infovoldik Infovoldik hispaania 16-10-2023
Toote omadused Toote omadused hispaania 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 23-06-2020
Infovoldik Infovoldik tšehhi 16-10-2023
Toote omadused Toote omadused tšehhi 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 23-06-2020
Infovoldik Infovoldik taani 16-10-2023
Toote omadused Toote omadused taani 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande taani 23-06-2020
Infovoldik Infovoldik saksa 16-10-2023
Toote omadused Toote omadused saksa 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande saksa 23-06-2020
Infovoldik Infovoldik eesti 16-10-2023
Toote omadused Toote omadused eesti 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande eesti 23-06-2020
Infovoldik Infovoldik kreeka 16-10-2023
Toote omadused Toote omadused kreeka 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 23-06-2020
Infovoldik Infovoldik prantsuse 16-10-2023
Toote omadused Toote omadused prantsuse 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 23-06-2020
Infovoldik Infovoldik itaalia 16-10-2023
Toote omadused Toote omadused itaalia 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 23-06-2020
Infovoldik Infovoldik läti 16-10-2023
Toote omadused Toote omadused läti 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande läti 23-06-2020
Infovoldik Infovoldik leedu 16-10-2023
Toote omadused Toote omadused leedu 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande leedu 23-06-2020
Infovoldik Infovoldik ungari 16-10-2023
Toote omadused Toote omadused ungari 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande ungari 23-06-2020
Infovoldik Infovoldik malta 16-10-2023
Toote omadused Toote omadused malta 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande malta 23-06-2020
Infovoldik Infovoldik hollandi 16-10-2023
Toote omadused Toote omadused hollandi 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 23-06-2020
Infovoldik Infovoldik poola 16-10-2023
Toote omadused Toote omadused poola 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande poola 23-06-2020
Infovoldik Infovoldik portugali 16-10-2023
Toote omadused Toote omadused portugali 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande portugali 23-06-2020
Infovoldik Infovoldik rumeenia 16-10-2023
Toote omadused Toote omadused rumeenia 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 23-06-2020
Infovoldik Infovoldik slovaki 16-10-2023
Toote omadused Toote omadused slovaki 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 23-06-2020
Infovoldik Infovoldik sloveeni 16-10-2023
Toote omadused Toote omadused sloveeni 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 23-06-2020
Infovoldik Infovoldik soome 16-10-2023
Toote omadused Toote omadused soome 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande soome 23-06-2020
Infovoldik Infovoldik rootsi 16-10-2023
Toote omadused Toote omadused rootsi 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 23-06-2020
Infovoldik Infovoldik norra 16-10-2023
Toote omadused Toote omadused norra 16-10-2023
Infovoldik Infovoldik islandi 16-10-2023
Toote omadused Toote omadused islandi 16-10-2023
Infovoldik Infovoldik horvaadi 16-10-2023
Toote omadused Toote omadused horvaadi 16-10-2023
Avaliku hindamisaruande Avaliku hindamisaruande horvaadi 23-06-2020

Vaadake dokumentide ajalugu